RxDoctor Payments Data

Chelise Black, NP

Family · Ogden, UTNPI 1952811515

Payments from drug & device makers

$626in general payments, 2019–2025

Across 28 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BETA Bionics, Inc.$149
  • Medtronic$144
  • Tandem Diabetes Care, Inc.$76
  • Lilly USA, LLC$60
  • Abbott$44
  • Novartis$38
  • plus $116 from 6 others

What the payments were for

  • Food & beverage$626100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$626 in reported general payments places this provider in the 60th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$48,843
Medicare patients
121
Services billed
1,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide171$189,416
OzempicSemaglutide182$178,361
TrulicityDulaglutide156$173,741
JardianceEmpagliflozin143$155,953
Humalog Kwikpen U-200Insulin Lispro48$144,535
Tresiba Flextouch U-200Insulin Degludec38$99,555
Humulin R U-500 KwikpenInsulin Regular, Human31$70,717
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog55$50,685
TradjentaLinagliptin43$45,915
Tresiba Flextouch U-100Insulin Degludec42$38,193
Lantus SolostarInsulin Glargine,hum.Rec.Anlog162$35,932
JanuviaSitagliptin Phosphate40$35,166
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$31,663
FarxigaDapagliflozin Propanediol37$30,114
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$28,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$60$387,454429 claims
Novo NordiskOzempic, Novolog, Fiasp$15$202,270234 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus, Admelog$14$37,57877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,460 family providers in Utah.

Other family in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →